Dopamine: hormone of happiness or source of disease?

Oguzhan Koçer; İmran Uysal; Musa Türkmen; Şevket Sümer; İrem Oğuz-Uysal; Abdullah Ozan Polat; Emre Sevindik; Ali Erdem Şabik; Hasan Akgül; Mustafa Sevindik

doi:10.56782/pps.928

Published : 2026-10-19

Vol. 24 No. 4 (2026)

Dopamine: hormone of happiness or source of disease?

Oguzhan Koçer

İmran Uysal

Musa Türkmen

Şevket Sümer

İrem Oğuz-Uysal

Abdullah Ozan Polat

Emre Sevindik

Ali Erdem Şabik

Hasan Akgül

Mustafa Sevindik

DOI: https://doi.org/10.56782/pps.928

Abstract

Dopamine, a critical neurotransmitter in both the central and peripheral nervous systems, plays a vital role in regulating physiological and psychological processes, including reward mechanisms, motivation, motor control, and cognitive functions. Imbalances in dopamine levels are associated with various neurological and psychiatric disorders, such as Parkinson's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD). This review comprehensively examines dopamine's biosynthesis, pharmacological effects, pharmacokinetics, and its impact on hormonal regulation and health. Dopamine's synthesis from tyrosine involves key enzymes, and its effects are mediated through dopamine receptors (D1-like [D1, D5] and D2-like [D2, D3, D4]), as well as adrenergic receptors, depending on the dosage. Low doses induce renal and mesenteric vasodilation, while higher doses stimulate cardiac contractility and systemic vasoconstriction. However, dopamine's pharmacokinetics exhibit significant interindividual variability, influenced by factors such as renal and hepatic function, complicating its clinical use. Dopamine also modulates hormonal release, including prolactin, oxytocin, and vasopressin, and plays a role in conditions like schizophrenia, depression, and anxiety. During pregnancy, dopamine regulates placental function, fetal development, and maternal hemodynamics, though its use requires caution due to potential fetal risks. This review highlights the need for personalized dosing strategies and further research to optimize dopamine's therapeutic applications while minimizing adverse effects. In addition, a clear distinction is made between physiological dopamine signaling and therapeutic dopamine administration, particularly in terms of pharmacokinetics and dosing considerations. This study is designed as a narrative review based on peer-reviewed literature indexed in major scientific databases, including PubMed, Scopus, and Web of Science, to provide a comprehensive overview of current knowledge on dopamine. Advances in receptor-selective therapeutic strategies, along with ongoing challenges related to optimal dosing and safety profiles, highlight the need for more precise and individualized approaches in dopamine-based treatments across neurological, psychiatric, and critical care settings.

Keywords:

Dopamine, Neurotransmitter, Central nervous system, Pregnancy, Pharmacokinetics, Therapeutic applications

Similar Articles

Mateusz Sobczyk, Mikołaj Porzak, Daria Żuraw, Alicja Sodolska, Paulina Oleksa, Kacper Jasiński, Small intestinal bacterial overgrowth – current, novel and possible future methods of treatment and diagnosis , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Barbara Krzemińska, Gabriela Szewczyk, Cotoneaster horizontalis Decne. (Rosaceae) - medicinal or just ornamental species? , Prospects in Pharmaceutical Sciences: Vol. 22 No. 2 (2024)
Arzu Birinci Yildirim, Ayca Cimen, Yavuz Baba, Arzu Turker, Natural- and in vitro-grown Filipendula ulmaria (L.) Maxim: evaluation of pharmaceutical potential (antibacterial, antioxidant and toxicity) and phenolic profiles , Prospects in Pharmaceutical Sciences: Vol. 22 No. 1 (2024)
Natalia Cichoń, Dominika Lach, Michał Bijak Bijak, Paulina Rzeźnicka, Joanna Saluk, SIMILARITIES AND DIFFERENCES IN ANTIPLATELET THERAPY IN ACUTE CORONARY SYNDROMES AND ISCHEMIC STROKE , Prospects in Pharmaceutical Sciences: Vol. 14 No. 4 (2016)
Dominika Łaszczyca, Paradowska Paradowska, Katerina Makarova, ENVIRONMENTAL CONTAMINATION WITH BISPHENOL A , Prospects in Pharmaceutical Sciences: Vol. 13 No. 1 (2015)
Joanna J. Sajkowska, Katarzyna Paradowska, MULTIPLE ACTIVITIES OF VITAMIN D , Prospects in Pharmaceutical Sciences: Vol. 12 No. 1 (2014)
Jadwiga Turło, FUNGAL BIOTECHNOLOGY. APPLICATIONS IN PHARMACY AND SUPPLEMENTATION , Prospects in Pharmaceutical Sciences: Vol. 11 No. 3 (2013)
Magda Izydorczak, Joanna Stefańska, ANTIMICROBIAL AGENT TRICLOSAN - ACTIVITY, APPLICATIONS AND HAZARDS , Prospects in Pharmaceutical Sciences: Vol. 5 No. 2 (2007)
Piotr Bojanowski, Piotr F. J. Lipiński, Paweł Czekała, Dariusz Plewczyński, MULTITARGET DRUGS – A NEW PARADIGM IN DRUG DESIGN , Prospects in Pharmaceutical Sciences: Vol. 11 No. 1 (2013)
Arzu Birinci Yildirim, Arzu Ucar Turker , Evaluation of pharmaceutical potentials of naturally and in vitro-grown wild strawberry (Fragaria vesca L.) , Prospects in Pharmaceutical Sciences: Vol. 23 No. 3 (2025)

<< < 5 6 7 8 9 10 11 12 13 14 > >>

You may also start an advanced similarity search for this article.

Details

References

Statistics

Authors

Download files

PDF

Citation rules

Koçer, O., Uysal, İmran, Türkmen, M., Sümer, Şevket, Oğuz-Uysal, İrem, Polat, A. O., … Sevindik, M. (2026). Dopamine: hormone of happiness or source of disease?. Prospects in Pharmaceutical Sciences, 24(4), 1–9. https://doi.org/10.56782/pps.928

Altmetric indicators

Cited by / Share

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License.

References

1. Kourosh-Arami, M.; Komaki, A.; Zarrindast, M-R. Dopamine as a potential target for learning and memory: contributing to related neurological disorders. CNS Neurol. Disord. Drug Targets 2023, 22(4), 558-576. DOİ: 10.2174/1871527321666220418115503

2. Chen, H.; Li, J.; Huang, Z.; Fan, X.; Wang, X.; Chen, X.; Liu, Y. Dopaminergic system and neurons: role in multiple neurological diseases. Neuropharmacology 2024, 260, Art. No: 110133. DOİ: 10.1016/j.neuropharm.2024.110133

3. Franco, R.; Reyes-Resina, I.; Navarro, G. Dopamine in health and disease: Much more than a neurotransmitter. Biomedicines 2021, 9, Art. No: 109. DOİ: 10.3390/biomedicines9020109

4. Latif, S.; Jahangeer, M.; Razia, D.M.; Ashiq, M.; Ghaffar, A.; Akram, M.; Ansari, M. A.Dopamine in Parkinson's disease. Clin. Chim. Acta. 2021, 522, 114-126. DOİ: 10.1016/j.cca.2021.08.009

5. Humińska-Lisowska, K. Dopamine in sports: a narrative review on the genetic and epigenetic factors shaping personality and athletic performance. Int. J. Mol. Sci. 2024, 25, Art. No: 11602. DOİ: 10.3390/ijms252111602

6. Hornykiewicz, O. Dopamine (3-hydroxytyramine) and brain function. Pharmacol. Rev. 1966, 18, 925-964. DOİ: 10.1016/S0031-6997(25)07154-6

7. Missale, C.; Nash, S. R.; Robinson, S. W.; Jaber, M.; Caron, M. G. Dopamine receptors: from structure to function. Physiol. Rev. 1998, 78, 189-225. DOİ: 10.1152/physrev.1998.78.1.189

8. Schultz, W. Multiple dopamine functions at different time courses. Annu. Rev. Neurosci. 2007, 30, 259-288. DOİ: 10.1146/annurev.neuro.28.061604.135722

9. Strange, P.G. Dopamine receptors: structure and function. Prog. Brain Res. 1993, 99, 167-179. DOİ: 10.1016/S0079-6123(08)61345-X

10. Vallone, D.; Picetti, R.; Borrelli, E. Structure and function of dopamine receptors. Neurosci. Biobehav. Rev. 2000, 24, 125-132. DOİ: 10.1016/S0149-7634(99)00063-9

11. Bertoldi, M. Mammalian Dopa decarboxylase: structure, catalytic activity and inhibition. Arch. Biochem. Biophys. 2014, 546, 1-7. DOİ: 10.1016/j.abb.2013.12.020

12. Daubner, S.C.; Le, T.; Wang, S. Tyrosine hydroxylase and regulation of dopamine synthesis. Arch. Biochem. Biophys. 2011, 508(1), 1-12. DOİ: 10.1016/j.abb.2010.12.017

13. Feldman, R.S.; Meyer, J.S., Quenzer, L.F. Principles of neuropsychopharmacology. Sinauer Associates, 1997.

14. Gjedde, A.; Reith, J.; Dyve, S.; Léger, G.; Guttman, M.; Diksic, M.; Kuwabara, H. Dopa decarboxylase activity of the living human brain. Proc. Natl. Acad. Sci. 1991, 88, 2721-2725. DOİ: 10.1073/pnas.88.7.2721

15. Iuvone, P.M.; Galli, C.; Garrison-Gund, C.; Neff, N. Light stimulates tyrosine hydroxylase activity and dopamine synthesis in retinal amacrine neurons. Science 1978, 202, 901-902. DOİ: 10.1126/science.30997

16. Xu, Y.; Stokes, A.H.; Roskoski, JrR.; Vrana, K.E. Dopamine, in the presence of tyrosinase, covalently modifies and inactivates tyrosine hydroxylase. J. Neurosci. Res. 1998, 54, 691-697. DOİ: 10.1002/(SICI)1097-4547(19981201)54:5<691::AID-JNR14>3.0.CO;2-F

17. Lindenmayer, J-P. The pathophysiology of agitation. J. Clin. Psychiatry. 2000, 61(Suppl. 14), 5-10.

18. Laruelle, M.; Kegeles, L.S.; ABI‐DARGHAM, A. Glutamate, dopamine, and schizophrenia: from pathophysiology to treatment. Ann. N. Y. Acad. Sci. 2003, 1003, 138-158. DOİ: 10.1196/annals.1300.063

19. Winterer, G.; Weinberger, D.R. Genes, dopamine and cortical signal-to-noise ratio in schizophrenia. Trends Neurosci. 2004, 27, 683-690. DOİ: 10.1016/j.tins.2004.08.002

20. Cousins, D.A.; Butts, K.; Young, A.H. The role of dopamine in bipolar disorder. Bipolar Disord. 2009, 11, 787-806. DOİ: 10.1111/j.1399-5618.2009.00760.x

21. Wood, L.D. Clinical review and treatment of select adverse effects of dopamine receptor agonists in Parkinson’s disease. Drugs Aging 2010, 27, 295-310.

22. Miyake, N.; Thompson, J.; Skinbjerg, M.; Abi‐Dargham, A. Presynaptic dopamine in schizophrenia. CNS Neurosci. Ther. 2011, 17, 104-109. DOİ: 10.1111/j.1755-5949.2010.00230.x

23. Volkow, N. D.; Wang, G. J.; Newcorn, J. H.; Kollins, S. H.; Wigal, T. L.; Telang, F.; Swanson, J. M. Motivation deficit in ADHD is associated with dysfunction of the dopamine reward pathway. Mol. Psychiatry 2011, 16, 1147-1154.

24. Moraga-Amaro, R.; Gonzalez, H.; Pacheco, R.; Stehberg, J. Dopamine receptor D3 deficiency results in chronic depression and anxiety. Behav. Brain Res. 2014, 274, 186-193. DOİ: 10.1016/j.bbr.2014.07.055

25. Weinstein, J. J.; Chohan, M. O.; Slifstein, M.; Kegeles, L. S.; Moore, H.; Abi-Dargham, A. Pathway-specific dopamine abnormalities in schizophrenia. Biol. Psychiatry 2017, 81, 31-42. DOİ: 10.1016/j.biopsych.2016.03.2104

26. You, Y.; Zhang, H.; Xuan, A.; Zhang, J.; Fu, C., Sun, M.; Xu, J. Changes of dopamine D2 receptor in patients with insomnia and its clinical significance. Chin. J. Nucl. Med. Mol. Imaging 2019, 39, 385-390.

27. Schmack, K.; Bosc, M.; Ott, T.; Sturgill, J.; Kepecs, A. Striatal dopamine mediates hallucination-like perception in mice. Science 2021, 372, Art. No: eabf4740. DOİ: 10.1126/science.abf4740

28. Srivastav, S.; Cui, X.; Varela, R.B.; Kesby, J.P.; Eyles, D. Increasing dopamine synthesis in nigrostriatal circuits increases phasic dopamine release and alters dorsal striatal connectivity: implications for schizophrenia. Schizophrenia 2023, 9, Art. No: 69.

29. Howes, O.D.; McCutcheon, R.; Owen, M.J.; Murray, R.M. The role of genes, stress, and dopamine in the development of schizophrenia. Biol. Psychiatry 2017, 81, 9-20. DOİ: 10.1016/j.biopsych.2016.07.014

30. Woodward, N. D.; Cowan, R. L.; Park, S.; Ansari, M. S.; Baldwin, R. M., Li, R.; Zald, D. H. Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. Am. J. Psychiatry 2011, 168, 418-426. DOİ: 10.1176/appi.ajp.2010.10020165

31. Teleanu, R.I.; Niculescu, A-G.; Roza, E.; Vladâcenco, O.; Grumezescu, A.M.; Teleanu, D.M. Neurotransmitters—key factors in neurological and neurodegenerative disorders of the central nervous system. Int. J. Mol. Sci. 2022, 23, Art. No: 5954. DOİ: 10.3390/ijms23115954

32. Arnsten, A.F.; Rubia, K. Neurobiological circuits regulating attention, cognitive control, motivation, and emotion: disruptions in neurodevelopmental psychiatric disorders. J. Am. Acad. Child. Adolesc. Psychiatry 2012, 51, 356-367. DOİ: 10.1016/j.jaac.2012.01.008

33. Kalia, L.V.; Lang, A.E. Parkinson's disease. The Lancet 2015, 386, 896-912. DOİ: 10.1016/S0140-6736(14)61393-3

34. Howes, O.D.; Dawkins, E.; Lobo, M.C.; Kaar, S.J.; Beck, K. New drug treatments for schizophrenia: a review of approaches to target circuit dysfunction. Biol. Psychiatry 2024, 96, 638-650. DOİ: 10.1016/j.biopsych.2024.05.014

35. Berk, M.; Dodd, S.; Kauer‐Sant’anna, M.; Malhi, G. S.; Bourin, M.; Kapczinski, F.; Norman, T. Dopamine dysregulation syndrome: implications for a dopamine hypothesis of bipolar disorder. Acta Psychiatr. Scand. 2007, 116, 41-49. DOİ: 10.1111/j.1600-0447.2007.01058.x

36. Holla, S.N.; Arivazhahan, A. Pharmacotherapy of Depression and Anxiety Disorders. Introduction to Basics of Pharmacology and Toxicology: Volume 2: Essentials of Systemic Pharmacology: From Principles to Practice. 2021, 193-204. DOİ: 10.1007/978-981-33-6009-9_10

37. Taylor, W. D.; Zald, D. H.; Felger, J. C.; Christman, S.; Claassen, D. O.; Horga, G.; Rutherford, B. R. Influences of dopaminergic system dysfunction on late-life depression. Mol. Psychiatry 2022, 27, 180-191. DOİ: 10.1038/s41380-021-01265-0

38. Newman, A.H.; Grundt, P.; Nader, M.A. Dopamine D3 receptor partial agonists and antagonists as potential drug abuse therapeutic agents. J. Med. Chem. 2005, 48, 3663-3679.

39. Dittmann, R.W.; Hage, A.; Pedraza, J.; Newcorn, J.H. Non-stimulants in the treatment of ADHD. In: Oxford textbook of attention deficit hyperactivity disorder. Banaschewski T., (ed.), Coghill, D., (ed.), Zuddas, A., (ed.) Oxford University Press, Oxford (UK); 2018, 393-401. DOİ: 10.1093/med/9780198739258.003.0042

40. Schwab, L.C.; Garas, S.N.; Drouin-Ouellet, J.; Mason, S.L.; Stott, S.R.; Barker, R.A. Dopamine and Huntington’s disease. Expert Rev. Neurother. 2015, 15, 445-458. DOİ: 10.1586/14737175.2015.1025383

41. Unti, E.; Mazzucchi, S.; Palermo, G.; Bonuccelli, U.; Ceravolo, R. Antipsychotic drugs in Huntington’s disease. Expert Rev. Neurother. 2017, 17, 227-237. DOİ: 10.1080/14737175.2016.1226134

42. Mogwitz, S.; Buse, J.; Wolff, N.; Roessner, V. Update on the pharmacological treatment of tics with dopamine-modulating agents. ACS Chem. Neurosci. 2018, 9(4), 651-672.

43. Bandelow, B. Current and Novel Psychopharmacological Drugs for Anxiety Disorders. Adv. Exp. Med. Biol. 2020, 1191, 347-365. DOI: 10.1007/978-981-32-9705-0_19

44. Garakani, A.; Murrough, J. W.; Freire, R. C.; Thom, R. P.; Larkin, K.; Buono, F. D.; Iosifescu, D. V. Pharmacotherapy of anxiety disorders: current and emerging treatment options. Front. Psychiatry 2020, 11, Art. No: 595584. DOİ: 10.3389/fpsyt.2020.595584

45. MacGregor, D.A.; Smith, T.E.; Prielipp, R.C.; Butterworth, J.F.; James, R.L.; Scuderi, P.E. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000, 92, 338-346. DOİ: 10.1097/00000542-200002000-00013

46. Järnberg, P.; Bengtsson, L.; Ekstrand, J.; Hamberger, B. Dopamine infusion in man. Plasma catecholamine levels and pharmacokinetics. Acta Anaesthesiol. Scand. 1981, 25, 328-331. DOİ: 10.1111/j.1399-6576.1981.tb01661.x

47. Johnston, A.J.; Steiner, L.A.; O’Connell, M.; Chatfield, D.A.; Gupta, A.K.; Menon, D.K. Pharmacokinetics and pharmacodynamics of dopamine and norepinephrine in critically ill head-injured patients. Intensive Care Med. 2004, 30, 45-50. DOİ: 10.1007/s00134-003-2032-4

48. Bhatt-Mehta, V.; Nahata, M.; McClead, R.; Menke, J. Dopamine pharmacokinetics in critically ill newborn infants. Eur. J. Clin. Pharmacol. 1991, 40, 593-597.

49. Zaroslinski, J.; Possley, L.; Schwartz, R.; Morris, R.; Carone, F.; Browne, R. The pharmacology and subacute toxicology of dopamine. Proc. R. Soc. Med. 1977, 70, 2-6. DOİ: 10.1177/00359157770700S202

50. Dasta, J.F.; Kirby, M.G. Pharmacology and therapeutic use of low‐dose dopamine. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 1986, 6, 304-310. DOİ: 10.1002/j.1875-9114.1986.tb03492.x

51. Goldberg, L.I. Dopamine: receptors and clinical applications. Clin. Physiol. Biochem. 1985, 3(2-3), 120-126.

52. Goldberg, L.I. The role of dopamine receptors in the treatment of congestive heart failure. J. Cardiovasc. Pharmacol. 1989, 14, 19-27.

53. Sonne, J.; Goyal, A.; Lopez-Ojeda, W. Dopamine [Updated 2022 Jul 4]. StatPearls [Internet] Treasure Island (FL) Available online: https://www ncbi nlm nih gov/books/NBK535451/(accessed on 8 November 2022).

54. Bridges, T.; Hillhouse, E.; Jones, M. The effect of dopamine on neurohypophysial hormone release in vivo and from the rat neural lobe and hypothalamus in vitro. Physiol. J. 1976, 260, 647-666. DOİ: 10.1113/jphysiol.1976.sp011537

55. Leblanc, H.; Lachelin, G.; Abu-Fadil, S.; Yen, S. Effects of dopamine infusion on pituitary hormone secretion in humans. J. Clin. Endocrinol. Metab. 1976, 43, 668-674. DOİ: 10.1210/jcem-43-3-668

56. Previc, F.H. Prenatal influences on brain dopamine and their relevance to the rising incidence of autism. Med. Hypotheses 2007, 68, 46-60. DOİ: 10.1016/j.mehy.2006.06.041

57. Feldt–Rasmussen, U.; Mathiesen, E.R. Endocrine disorders in pregnancy: physiological and hormonal aspects of pregnancy. Best Pract. Res. Clin. Endocrinol. Metab. 2011, 25, 875-884. DOİ: 10.1016/j.beem.2011.07.004

58. Rosenfeld, C.S. The placenta‐brain‐axis. J. Neurosci. Res. 2021, 99, 271-283. DOİ: 10.1002/jnr.24603

59. Naz, F.; Malik, A.; Riaz, M.; Mahmood, Q.; Mehmood, M. H.; Rasool, G.; Abbas, M. Bromocriptine therapy: review of mechanism of action, safety and tolerability. Clin. Exp. Pharmacol. Physiol. 2022, 49, 903-922. DOİ: 10.1111/1440-1681.13678

60. Chang, K.J.; Seow K.M.; Chen K.H. Preeclampsia: Recent advances in predicting, preventing, and managing the maternal and fetal life-threatening condition. Int. J. Environ. Res. Public Health 2023, 20, Art. No: 2994. DOİ: 10.3390/ijerph20042994

61. Ye, Z.; Lu, X.; Deng, Y.; Wang, X.; Zheng, S.; Ren, H.; Zeng, C. In utero exposure to fine particulate matter causes hypertension due to impaired renal dopamine D1 receptor in offspring. Cell. Physiol. Biochem. 2018, 46, 148-159. DOİ: 10.1159/000488418

62. Lee, M. Dopamine and the kidney: ten years on. Clin. Sci. 1993, 84, 357-375. DOİ: 10.1042/cs0840357

63. Fishburne, Jr J.I.; Dormer, K.J.; Payne, G.G.; Gill, P.S.; Ashratzadeh, A.R.; Rossavik, I.K. Effects of amrinone and dopamine on uterine blood flow and vascular responses in the gravid baboon. Am. J. Obstet. Gynecol. 1988, 158, 829-835. DOİ: 10.1016/0002-9378(88)90079-8

64. Meyer, U.; Feldon, J. Prenatal exposure to infection: a primary mechanism for abnormal dopaminergic development in schizophrenia. Psychopharmacol. 2009, 206, 587-602. DOİ: 10.1007/s00213-009-1504-9

65. Fernstrom, J.D. Dietary amino acids and brain function. J. Am. Diet. Assoc. 1994, 94, 71-77. DOİ: 10.1016/0002-8223(94)92045-1

66. Bala, K. Beyond a Neurotransmitter: Physiological Role of Dopamine in Plants. In Neurotransmitters in Plant Signaling and Communication F. Baluška, S. Mukherjee, & A. Ramakrishna (Eds.). pp. 169–187. Springer, Cham. 2020. DOİ: 10.1007/978-3-030-54478-2_9

67. Briguglio, M.; Dell’Osso, B.; Panzica, G.; Malgaroli, A.; Banfi, G.; Zanaboni Dina, C.; Porta, M. Dietary neurotransmitters: a narrative review on current knowledge. Nutrients 2018, 10(5), Art. No: 591. DOİ: 10.3390/nu10050591

68. Salahuddin, M.; Abdel-Wareth, A.A.; Rashwan, A.K.; Hiramatsu, K.; Fulzele, S.; Lohakare, J. The role of egg-derived nutrients in Alzheimer's disease: Exploring potential benefits and biological insights. Food Biosci. 2024, 62, Art. No: 105096. DOİ: 10.1016/j.fbio.2024.105096

69. Saidi, V.; Sheikh-Zeinoddin, M.; Kobarfard, F.; Soleimanian-Zad, S.; Doost, A.S. Profiling of bioactive metabolites during the ripening of a semi-hard non-starter culture cheese to detect functional dietary neurotransmitters. Biocatal. Agric. Biotechnol. 2020, 28, Art. No: 101734. DOİ: 10.1016/j.bcab.2020.101734

70. Omaliko, P. C.; Ferket, P. R.; Ogundare, T. E.; Apalowo, O. O.; Enenya, I. G.; Iwuozo, O. C.; Fasina, Y. O. Impact of dietary fat types on expression levels of dopamine and serotonin transporters in the ileum of broiler chickens. Poult. Sci. 2024, 103, Art. No: 104114. DOİ: 10.1016/j.psj.2024.104114

71. Arslan, J.; Gilani, A. U. H.; Jamshed, H.; Khan, S. F.; Kamal, M. A. Edible nuts for memory. Curr. Pharm. Des. 2020, 26, 4712-4720. DOİ: 10.2174/1381612826666200806095649

72. Samanta, S.; Sarkar, T.; Chakraborty, R.; Rebezov, M.; Shariati, M. A.; Thiruvengadam, M.; Rengasamy, K. R. Dark chocolate: An overview of its biological activity, processing, and fortification approaches. Curr. Res. Food Sci. 2022, 5, 1916-1943. DOİ: 10.1016/j.crfs.2022.10.017

73. Kumar, S.; Mishra, T.; Prajapati, A.; Sethi, P. Nutrition, Neurotransmitters, and Behavior. In Nutrition and Psychiatric Disorders, W. Mohamed & F. Kobeissy (Eds.), pp. 89–108. Springer, Singapore. DOİ: 10.1007/978-981-19-5021-6

74. Marques, A.; Marconcin, P.; Werneck, A. O.; Ferrari, G.; Gouveia, É. R.; Kliegel, M.; Ihle, A. Bidirectional association between physical activity and dopamine across adulthood — A systematic review. Brain Sci. 2021, 11, Art. No: 829. DOİ: 10.3390/brainsci11070829

75. Lv, L.; Tan, X.; Peng, X.; Bai, R.; Xiao, Q.; Zou, T.; Wang, C. The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease. Transl. Neurodegener. 2020, 9, Art. No: 34. DOİ: 10.1186/s40035-020-00213-2

76. Aggarwal, A. Hypothalamo-pituitary-adrenal axis and brain during stress, yoga and meditation. Int. J. Health Clin. Res. 2020, 3, 96-103.

77. Lima, M.M. Sleep disturbances in Parkinson's disease: the contribution of dopamine in REM sleep regulation. Sleep Med. Rev. 2013, 17, 367-375. DOİ: 10.1016/j.smrv.2012.10.006

Dopamine: hormone of happiness or source of disease?

Oguzhan Koçer

İmran Uysal

Musa Türkmen

Şevket Sümer

İrem Oğuz-Uysal

Abdullah Ozan Polat

Emre Sevindik

Ali Erdem Şabik

Hasan Akgül

Mustafa Sevindik

Abstract

Keywords:

Most read articles by the same author(s)

Similar Articles

Oguzhan Koçer

İmran Uysal

Musa Türkmen

Şevket Sümer

İrem Oğuz-Uysal

Abdullah Ozan Polat

Emre Sevindik

Ali Erdem Şabik

Hasan Akgül

Mustafa Sevindik